+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Syphilis Immunoassay Diagnostic Market - Global Forecast 2026-2032- Product Image
Syphilis Immunoassay Diagnostic Market - Global Forecast 2026-2032- Product Image
Sale

Syphilis Immunoassay Diagnostic Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995105
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Syphilis Immunoassay Diagnostic Market is projected to reach USD 611.81 Million in 2026. It is expected to continue growing at a CAGR of 5.95%, reaching USD 867.44 Million by 2032.

Syphilis immunoassay diagnostics are moving from a confirmatory laboratory tool to a front-line component of sexually transmitted infection (STI) control, prenatal screening, blood safety, and high-throughput clinical testing. The market is anchored by treponemal enzyme immunoassays (EIA), chemiluminescent immunoassays (CLIA), rapid immunochromatographic tests, and dual HIV/syphilis point-of-care assays used alongside non-treponemal tests such as RPR and VDRL for disease activity assessment.

Demand is supported by a documented global resurgence of syphilis. The World Health Organization (WHO) estimates that 8 million adults aged 15-49 acquired syphilis in 2022, while the U.S. Centers for Disease Control and Prevention (CDC) reported sustained increases in total syphilis and congenital syphilis in recent surveillance cycles. For diagnostic manufacturers, the opportunity is strongest where automation, reflex testing algorithms, pregnancy screening, decentralized testing, antimicrobial stewardship, and public health surveillance converge.

Transformative Shifts in the Syphilis Testing Landscape

The competitive landscape is shifting toward automated, high-throughput treponemal screening platforms that support reverse-sequence algorithms in large laboratories. Hospitals and reference labs increasingly prefer immunoassays that integrate with laboratory information systems, reduce manual interpretation, support standardized quality control, and deliver consistent throughput across prenatal care, emergency departments, sexual health clinics, and blood screening environments.

At the same time, access gaps are accelerating demand for rapid syphilis tests and dual HIV/syphilis assays in antenatal care and community settings. WHO guidance supporting dual testing for pregnant women and key populations is reinforcing the need for affordable, easy-to-use assays that can expand same-day treatment linkage. Manufacturers that balance analytical performance, regulatory compliance, cost efficiency, stable supply, and field usability are best positioned to capture demand.

Cumulative Impact of Artificial Intelligence on Syphilis Diagnostics

Artificial intelligence is not replacing serological confirmation, but it is increasingly shaping the syphilis immunoassay diagnostic value chain. AI-enabled analytics can improve demand planning, reagent inventory management, quality-control trend detection, sample routing, and reflex-testing workflows. In high-volume laboratories, machine learning can help flag unusual result patterns, reduce turnaround-time bottlenecks, and support automated review rules under validated governance.

For manufacturers and health systems, the cumulative impact of AI is strongest when embedded around the test ecosystem rather than the assay chemistry itself. AI-supported epidemiological dashboards, prenatal screening follow-up, and risk-based outreach can make syphilis immunoassay results more actionable for clinicians and public health teams. However, adoption depends on data privacy safeguards, bias monitoring, cybersecurity, clinical validation, interoperability, and clear separation between decision support and regulated diagnostic claims.

Key Regional Insights for Syphilis Immunoassay Diagnostics

Asia-Pacific is a high-priority region because large populations, expanding universal health coverage programs, and maternal-child health initiatives are increasing demand for scalable STI diagnostics. China, India, Japan, South Korea, Australia, and ASEAN markets show different adoption curves, with large centralized laboratories favoring automated treponemal immunoassays and rural or outreach programs requiring rapid point-of-care testing. WHO has emphasized the role of antenatal syphilis screening in eliminating mother-to-child transmission, making pregnancy testing pathways a major demand driver across lower-resource and mixed-access health systems.

North America remains one of the most commercially mature regions, driven by CDC screening recommendations, strong reference-lab infrastructure, and rising congenital syphilis prevention efforts in the United States and Canada. Latin America is shaped by public-sector procurement, prenatal screening expansion, and the need for affordable rapid assays in Brazil, Mexico, and underserved areas. Europe benefits from established laboratory networks, EU regulatory harmonization under the IVDR, and strong STI surveillance coordinated through national agencies and regional monitoring systems. The Middle East is advancing through hospital modernization, digital health investment, and GCC public health programs, while Africa represents a critical access region where WHO-aligned dual HIV/syphilis testing, antenatal screening, and donor-supported programs are central to reducing missed diagnosis and congenital transmission.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are characterized by a dual need for centralized immunoassay capacity in urban hospitals and decentralized rapid testing in primary care, antenatal services, and outreach programs. The GCC is investing in advanced laboratory infrastructure, digital health systems, and preventive screening, making it attractive for automated CLIA and EIA platforms with service reliability, multilingual workflow support, and regulatory compliance.

The European Union is shaped by IVDR requirements, coordinated surveillance, and strong demand for validated, traceable diagnostic workflows. BRICS countries combine high population scale with uneven access, creating opportunities for tiered portfolios that include automated platforms, rapid tests, public-sector procurement readiness, and localized manufacturing or distribution partnerships. G7 countries emphasize quality, automation, antimicrobial stewardship, congenital syphilis prevention, and laboratory connectivity, while NATO-aligned markets generally benefit from procurement discipline, reference-lab capacity, and cross-border preparedness frameworks that support resilient diagnostic supply chains and continuity of essential testing.

Key Country Insights for Priority Syphilis Diagnostic Markets

The United States is the most visible demand driver due to high reported syphilis and congenital syphilis burden, broad laboratory automation, and intensive public health response. Canada prioritizes STI screening access across provinces and remote communities, while Mexico and Brazil combine high public-sector demand with opportunities for affordable rapid testing and prenatal screening scale-up. These North and Latin American countries require diagnostic portfolios that can support both centralized immunoassay workflows and decentralized testing in populations with barriers to follow-up.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on sophisticated laboratory networks, quality-assured immunoassays, and surveillance-based screening strategies, while Russia represents a large testing environment supported by centralized public health infrastructure. In Asia-Pacific, China and India offer scale through large public and private healthcare systems, Japan and South Korea emphasize quality, automation, and laboratory efficiency, and Australia combines strong sexual health services with remote-care testing needs. Across these countries, successful syphilis immunoassay diagnostic portfolios align product format with testing setting, reimbursement environment, regulatory pathway, clinician workflow, and public health priorities.

Actionable Recommendations for Diagnostic Industry Leaders

Industry leaders should design portfolios that span automated treponemal immunoassays, confirmatory workflow support, and rapid point-of-care solutions. A single-platform strategy is increasingly insufficient because syphilis testing demand is distributed across reference laboratories, hospitals, prenatal clinics, blood banks, mobile outreach programs, correctional health settings, and low-resource communities.

Manufacturers should invest in IVDR-ready evidence packages, clinical performance studies across diverse populations, digital connectivity, supply continuity, quality management, and partnerships with ministries of health, NGOs, and reference laboratories. Commercial teams should position syphilis immunoassay diagnostics around measurable outcomes: faster diagnosis, reduced congenital syphilis risk, improved treatment linkage, lower manual workload, more reliable STI surveillance, and stronger continuity between screening, confirmation, treatment, and follow-up.

Research Methodology for Syphilis Immunoassay Diagnostic Analysis

This executive summary is based on triangulated secondary research from globally recognized public health and regulatory sources, including WHO STI surveillance and testing guidance, CDC STI surveillance reports and screening recommendations, ECDC communicable disease surveillance, national health agencies, peer-reviewed literature, and regulatory frameworks such as FDA oversight and the EU In Vitro Diagnostic Regulation.

Market interpretation was developed through product-category mapping, regional policy review, epidemiological burden assessment, screening pathway analysis, and technology trend evaluation. Claims were limited to verified, publicly available evidence and established diagnostic practice, with emphasis on syphilis immunoassay platforms, rapid tests, reflex algorithms, prenatal screening, congenital syphilis prevention, laboratory automation, and digital workflow integration.

Conclusion: Strategic Outlook for Syphilis Immunoassay Diagnostics

Syphilis immunoassay diagnostics are becoming central to the global response against rising STI burden and preventable congenital infection. The market’s direction is defined by automation in high-volume laboratories, rapid testing in decentralized care, and integrated workflows that connect diagnosis to treatment, surveillance, and maternal-child health outcomes.

For diagnostic manufacturers, progress will favor clinically validated, scalable, digitally enabled, and regionally adaptable solutions. Organizations that combine assay performance with procurement readiness, regulatory discipline, AI-supported operations, and strong public health partnerships will be best positioned in the evolving syphilis diagnostic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Syphilis Immunoassay Diagnostic Market, by Product Type
7.1. Introduction
7.2. Instruments
7.2.1. Automated Analyzer
7.2.2. Point Of Care Device
7.2.3. Semi-Automated Analyzer
7.3. Kits
7.3.1. Control Kits
7.3.2. Ready-To-Use Kits
7.3.3. Reagent Kits
8. Syphilis Immunoassay Diagnostic Market, by Technology
8.1. Introduction
8.2. Chemiluminescence Immunoassay
8.3. Enzyme-Linked Immunosorbent Assay
8.4. Fluorescence Immunoassay
9. Syphilis Immunoassay Diagnostic Market, by Sample Type
9.1. Introduction
9.2. Serum
9.3. Whole Blood
9.4. Plasma
10. Syphilis Immunoassay Diagnostic Market, by Test Type
10.1. Introduction
10.2. Treponemal Immunoassays
10.3. Non-Treponemal Immunoassays
11. Syphilis Immunoassay Diagnostic Market, by Disease Stage
11.1. Introduction
11.2. Primary Syphilis
11.3. Secondary Syphilis
11.4. Latent Syphilis
11.5. Tertiary Syphilis
12. Syphilis Immunoassay Diagnostic Market, by End User
12.1. Introduction
12.2. Blood Banks
12.3. Clinics
12.4. Diagnostic Laboratories
12.5. Hospitals
13. Syphilis Immunoassay Diagnostic Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Syphilis Immunoassay Diagnostic Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Syphilis Immunoassay Diagnostic Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Becton, Dickinson and Company
17.3. Bio-Rad Laboratories, Inc.
17.4. bioMérieux SA
17.5. Chembio Diagnostics, Inc.
17.6. Creative Diagnostics
17.7. DiaSorin S.p.A.
17.8. F. Hoffmann-La Roche Ltd.
17.9. Fujirebio Holdings, Inc.
17.10. Grifols, S.A.
17.11. Meridian Bioscience, Inc.
17.12. OraSure Technologies, Inc.
17.13. Ortho Clinical Diagnostics Holdings plc
17.14. QuidelOrtho Corporation
17.15. SD Biosensor, Inc.
17.16. Sekisui Diagnostics, LLC
17.17. Siemens Healthineers AG
17.18. Thermo Fisher Scientific Inc.
17.19. Trinity Biotech plc
List of Figures
FIGURE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AUTOMATED ANALYZER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AUTOMATED ANALYZER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AUTOMATED ANALYZER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL POINT OF CARE DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL POINT OF CARE DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL POINT OF CARE DEVICE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SEMI-AUTOMATED ANALYZER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SEMI-AUTOMATED ANALYZER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SEMI-AUTOMATED ANALYZER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CONTROL KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CONTROL KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CONTROL KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL READY-TO-USE KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL READY-TO-USE KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL READY-TO-USE KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL REAGENT KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL REAGENT KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL REAGENT KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NON-TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NON-TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NON-TREPONEMAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRIMARY SYPHILIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PRIMARY SYPHILIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PRIMARY SYPHILIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SECONDARY SYPHILIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SECONDARY SYPHILIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SECONDARY SYPHILIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LATENT SYPHILIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LATENT SYPHILIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LATENT SYPHILIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TERTIARY SYPHILIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TERTIARY SYPHILIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TERTIARY SYPHILIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BLOOD BANKS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BLOOD BANKS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BLOOD BANKS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 111. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 112. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 114. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 115. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 116. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 129. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 130. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 131. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 132. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 133. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 134. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 135. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 139. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 140. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 141. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 142. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 143. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 144. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 145. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 148. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 149. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 150. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 151. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 152. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 153. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 154. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 166. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 167. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 168. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 170. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 171. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 172. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 175. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 176. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 177. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 178. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 179. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 180. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 181. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 185. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 186. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 187. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 188. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 189. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 190. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 203. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 204. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 205. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 206. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 207. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 208. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 209. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 211. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 212. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 213. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 214. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 215. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 216. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 217. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 218. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 221. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 222. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 223. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 224. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 227. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 239. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 240. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 241. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 242. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 243. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 244. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 245. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 248. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 249. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 250. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 251. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 252. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 253. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 254. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 257. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 258. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 263. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 266. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 267. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 268. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 269. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 270. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 271. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 272. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 275. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 276. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 277. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 278. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 279. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 280. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 281. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 284. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 285. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 286. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 287. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 288. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 289. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 290. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 293. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 294. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 295. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 298. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 299. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 302. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 303. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 304. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 305. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 306. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 307. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 308. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 311. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 317. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 324. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 325. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 326. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
TABLE 328. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Chembio Diagnostics, Inc.
  • Creative Diagnostics
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Holdings, Inc.
  • Grifols, S.A.
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics Holdings plc
  • QuidelOrtho Corporation
  • SD Biosensor, Inc.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc

Table Information

Report AttributeDetails
No. of Pages185
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 611.81 Million
Forecasted Market Value ( USD ) by 2032 $ 867.44 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Syphilis Immunoassay Diagnostics Market Report 2026 - Product Image

Syphilis Immunoassay Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Syphilis Immunoassay Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Syphilis Immunoassay Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Syphilis Immunoassay Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Syphilis Immunoassay Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 189 Pages
  • Global
From
Syphilis Immunoassay Diagnostics - Global Strategic Business Report - Product Image

Syphilis Immunoassay Diagnostics - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Immunoassay Market - Global Forecast 2026-2032 - Product Image

Immunoassay Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From

About the Syphilis Immunoassay Market

The Syphilis Immunoassay market is a segment of the broader In Vitro Diagnostics (IVD) sector that focuses on the detection and diagnosis of syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum. Immunoassays are laboratory techniques used to detect specific antigens or antibodies in serum or plasma samples. These assays are essential diagnostic tools in the management of syphilis, allowing for early detection, confirmation of infection, and monitoring of treatment efficacy. This market includes both manual and automated testing platforms that can deliver rapid results and high-throughput screening. Due to the importance of timely and accurate syphilis screening, investments in research and development have led to the advancement of immunoassay technologies, with an emphasis on improving sensitivity, specificity, and ease of use. Several companies operate within the Syphilis Immunoassay market, each offering various testing solutions to suit different healthcare settings and diagnostic needs. Some prominent players in this market are Abbott Laboratories, which provides a range of diagnostic equipment and tests, Roche Diagnostics with their automated immunoassay systems, Siemens Healthineers known for their innovative laboratory diagnostics, Bio-Rad Laboratories offering a variety of immunoassay platforms, and Danaher Corporation, which operates under various brand names and has a diverse portfolio of diagnostic solutions. These companies are pivotal in shaping the landscape of syphilis diagnostics and continue to contribute to public health efforts through their products and services Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.